Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Lung Diseases 1Liposarcoma 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma 1Advanced or Metastatic Solid Malignancies 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

sitravatinib 1pembrolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced or Metastatic Solid Malignancies × sitravatinib × Clear all
NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Mirati Therapeutics Inc.

Phase 2/3 Completed
52 enrolled

Advanced or Metastatic Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡